AVEO Pharmaceuticals, Inc.
AVEO
AVEO was delisted on the 19th of January, 2023.
76 hedge funds and large institutions have $101M invested in AVEO Pharmaceuticals, Inc. in 2021 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 21 increasing their positions, 19 reducing their positions, and 9 closing their positions.
122% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 9
68% more capital invested
Capital invested by funds: $60.5M → $101M (+$41M)
38% more call options, than puts
Call options by funds: $7.28M | Put options by funds: $5.28M
17% more funds holding
Funds holding: 65 → 76 (+11)
11% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$12.9M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$8.32M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$6.7M |
| 4 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
+$2.59M |
| 5 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
+$2.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$9.71M |
| 2 |
JP Morgan Chase
New York
|
-$837K |
| 3 |
Squarepoint
New York
|
-$745K |
| 4 |
Millennium Management
New York
|
-$630K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$619K |
AVEO Hedge Fund Activity: Q1 2021 in Review
76 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals, Inc. (AVEO) for Q1 2021, worth a combined $101M — up 68% from $60.5M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new AVEO positions and 9 closed out — a net gain of 11 holders — while 21 added to existing stakes and 19 trimmed.
The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $12.9M. The largest seller was Sectoral Asset Management, cutting an estimated $9.71M.
- 76 institutional investors held AVEO Pharmaceuticals, Inc. (AVEO) as of Q1 2021, up from 65 in Q4 2020.
- Funds reported $101M of AVEO Pharmaceuticals, Inc. stock for Q1 2021, up 68% quarter-over-quarter.
- 20 funds opened new AVEO Pharmaceuticals, Inc. positions in Q1 2021 and 9 closed out, a net change of +11 holders.
- The largest AVEO Pharmaceuticals, Inc. buyer in Q1 2021 was Cormorant Asset Management, an estimated $12.9M added.
- The largest AVEO Pharmaceuticals, Inc. seller in Q1 2021 was Sectoral Asset Management, an estimated $9.71M sold.
Based on aggregated 13F filings for Q1 2021.